Media headlines about Vericel Corporation (NASDAQ:VCEL) have been trending somewhat negative on Tuesday, Alpha One reports. The research group, a unit of Accern, scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vericel Corporation earned a news sentiment score of -0.12 on Alpha One’s scale. Alpha One also assigned news coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected AlphaOne Sentiment’s analysis:
- Technical Indicator Scrutiny For Vericel Corp (VCEL) – Bulletin News (orobulletin.com)
- Drilling into the Technicals & Valuation For Vericel Corporation (NasdaqCM:VCEL) – Financial Newsweek (finnewsweek.com)
- Vericel Corporation (NasdaqCM:VCEL): VC in The Spotlight – Trion Journal (trionjournal.com)
- Vericel Corporation (NasdaqCM:VCEL) Profitability in Focus – Ozark Times (ozarktimes.com)
- Vericel Corporation (VCEL) stock uncovered monthly dynamic performance with growing progress of 7.84% – Stocks Gallery (stocksgallery.com)
Shares of Vericel Corporation (NASDAQ VCEL) traded down 0.909% during trading on Tuesday, reaching $2.725. 41,567 shares of the company’s stock were exchanged. Vericel Corporation has a 12-month low of $1.96 and a 12-month high of $4.55. The stock’s market cap is $89.29 million. The company has a 50 day moving average of $2.71 and a 200 day moving average of $2.77.
Vericel Corporation (NASDAQ:VCEL) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.12. The firm had revenue of $9.36 million for the quarter. Equities research analysts anticipate that Vericel Corporation will post ($0.80) EPS for the current year.
Separately, Needham & Company LLC restated a “buy” rating and issued a $6.00 target price (down from $9.00) on shares of Vericel Corporation in a research note on Monday, March 13th.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by sleekmoney and is owned by of sleekmoney. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sleekmoney.com/vericel-corporation-vcel-earns-media-sentiment-rating-of-0-12/1905375.html.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/vericel-corporation-vcel-earns-media-sentiment-rating-of-0-12/1905375.html
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.